Sangamo Therapeutics, Inc.
SGMO
$0.44
-$0.01-1.16%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -98.82% | 5,042.13% | 1,238.25% | 269.78% | 425.77% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -98.82% | 5,042.13% | 1,238.25% | 269.78% | 425.77% |
| Cost of Revenue | 1.48% | 11.81% | -30.89% | -53.49% | -51.42% |
| Gross Profit | -227.13% | 63.22% | 48.12% | 67.00% | 145.46% |
| SG&A Expenses | -9.68% | -36.28% | -14.52% | -26.01% | -36.42% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -1.22% | -6.00% | -26.84% | -47.83% | -48.48% |
| Operating Income | -377.09% | 53.15% | 39.74% | 58.28% | 120.83% |
| Income Before Tax | -426.12% | 44.64% | 37.79% | 60.67% | 110.46% |
| Income Tax Expenses | -282.95% | -63.51% | 21.43% | -56.99% | -93.07% |
| Earnings from Continuing Operations | -427.31% | 44.68% | 37.67% | 61.20% | 110.25% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -427.31% | 44.68% | 37.67% | 61.20% | 110.25% |
| EBIT | -377.09% | 53.15% | 39.74% | 58.28% | 120.83% |
| EBITDA | -346.02% | 54.27% | 40.12% | 59.08% | 125.04% |
| EPS Basic | -355.11% | 54.45% | 48.97% | 67.22% | 107.65% |
| Normalized Basic EPS | -285.35% | 57.31% | 46.28% | 66.07% | 118.98% |
| EPS Diluted | -387.00% | 54.45% | 48.97% | 65.86% | 106.78% |
| Normalized Diluted EPS | -290.74% | 57.31% | 46.28% | 66.07% | 118.45% |
| Average Basic Shares Outstanding | 46.04% | 25.99% | 22.14% | 18.33% | 17.60% |
| Average Diluted Shares Outstanding | 41.97% | 25.99% | 22.14% | 18.33% | 20.97% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |